We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 29 for:    fop

An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in FOP Subjects in France

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02979769
First Posted: December 2, 2016
Last Update Posted: February 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Clementia Pharmaceuticals Inc.
November 23, 2016
December 2, 2016
February 13, 2017
November 2016
December 2018   (Final data collection date for primary outcome measure)
Percentage of flare-ups with no new HO as assessed by low-dose CT scan [ Time Frame: Flare-up Day 84 ]
Same as current
Complete list of historical versions of study NCT02979769 on ClinicalTrials.gov Archive Site
  • Amount (volume) of new HO at the flare-up site as assessed by low-dose CT scan. [ Time Frame: baseline, Flare-up Day 84/end-of-treatment (EOT) ]
  • Amount (volume) of new HO overall as assessed by low-dose whole body CT scan, excluding head. [ Time Frame: baseline, Study Months 12 and 24 ]
  • Active range of motion measured by goniometer at the flare-up site. [ Time Frame: baseline, Flare-up Day 84/EOT ]
  • Range of motion as assessed by the Cumulative Analogue Joint Involvement Scale for FOP (CAJIS). [ Time Frame: baseline, Flare-up Day 84/EOT; Study Months 12 and 24 ]
  • Number of flare-ups per subject-month exposure. [ Time Frame: study start date to study end date (up to 24 months) ]
  • Subject and Investigator global assessment of movement. [ Time Frame: Flare-up Day 84/EOT ]
  • Age-appropriate patient-reported assessment of physical function. [ Time Frame: baseline, Flare-up days 28, 56, 84/EOT; Study Months 12 and 24 ]
  • Use of assistive devices and adaptations for daily living by FOP subjects. [ Time Frame: baseline, Flare-up Day 84/EOT; Study Months 12 and 24 ]
  • Plasma biomarker levels. [ Time Frame: baseline, Flare-up Days 28, 56, and 84/EOT; Study Months 12 and 24 ]
  • Presence of soft tissue swelling and/or cartilage by magnetic resonance imaging (or ultrasound). [ Time Frame: Flare-up Day 84/EOT ]
  • Pain at the flare-up site using a numeric rating scale for each symptom. [ Time Frame: baseline, Flare-up Days 14, 28, 42, 56, 70, and 84/EOT ]
  • Swelling at the flare-up site using a numeric rating scale for each symptom. [ Time Frame: baseline, Flare-up Days 14, 28, 42, 56, 70, and 84/EOT ]
  • Duration of active, symptomatic flare-up. [ Time Frame: subject-reported symptom start date to documented symptom end date assessed up to 84 days/EOT ]
  • Amount of new heterotopic bone formed at the original flare-up site as assessed by low-dose CT scan (or plain radiograph for those unable to undergo CT scan). [ Time Frame: baseline, Study Month 12 (Pediatric Cohort only) ]
  • Safety evaluation including adverse events and clinical safety laboratory parameters. [ Time Frame: Flare-up Days 1 (the first day of dosing), 7, 14, 28, 42, 56, 70, and 84/EOT; Study Months 3, 6, 9, 12, 15, 18, 21, and 24 ]
Same as current
Not Provided
Not Provided
 
An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in FOP Subjects in France
A Phase 2, Open-Label, Efficacy and Safety Study of an RARγ Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation (heterotopic ossification or HO) in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare-ups progressively restrict movement by locking joints leading to cumulative loss of function and disability. Mouse models of FOP have demonstrated the ability of retinoic acid receptor gamma (RARγ) agonists such as palovarotene (PVO) to prevent HO following injury. This 24-month study will (1) continue to follow FOP subjects from France who completed Clementia Study PVO-1A-201; (2) enroll up to eight additional new French subjects who have achieved at least 90% skeletal maturity; and (3) evaluate the ability of different palovarotene dosing regimens to prevent HO in these subjects.

The main objective of this Phase 2, open-label study is to evaluate the safety and efficacy of different palovarotene dosing regimens in subjects with FOP in France.

Adult Cohort subjects (those with at least 90% skeletal maturity) will be treated with 5 mg palovarotene daily for up to 24 months. Site visits will occur at baseline/screening and at Study Months 12 and 24; subjects will also be contacted by telephone every 3 months.

In the event of an eligible flare-up, Adult Cohort subjects will receive 20 mg palovarotene daily for 28 days, followed by 10 mg for 56 days. Dosing may be extended if the flare-up is not resolved by Flare-up Day 84 and continue until the flare-up resolves (at the end-of-treatment [EOT]). Dose reduction, as directed by the Investigator, may occur in the event of intolerable side effects.

The flare-up based dosing regimen for Pediatric Cohort subjects (those with less than 90% skeletal maturity) will be the same as for Adult Cohort subjects except doses will adjusted for weight. Pediatric subjects will not receive non-flare-up daily dosing until preliminary efficacy and safety data are obtained in the Adult Cohort. Site visits will occur at Flare-up Baseline and at Flare-up Day 84/EOT; subjects will also be contacted by telephone every 2 weeks.

Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Fibrodysplasia Ossificans Progressiva
  • Drug: Palovarotene dose level 1
    Palovarotene will be taken orally once daily at approximately the same time each day.
  • Drug: Palovarotene dose level 2
    Palovarotene will be taken orally once daily at approximately the same time each day.
  • Experimental: Palovarotene dose level 1
    Adult Cohort subjects (those with at least 90% skeletal maturity) will receive 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups.
    Intervention: Drug: Palovarotene dose level 1
  • Experimental: Palovarotene dose level 2
    During an eligible flare-up, Pediatric Cohort subjects (those with less than 90% skeletal maturity) will receive weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days.
    Intervention: Drug: Palovarotene dose level 2
Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, Chandraratna RA, Mishina Y, Enomoto-Iwamoto M, Pacifici M, Iwamoto M. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3. Erratum in: Nat Med. 2012 Oct;18(10):1592.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
17
December 2018
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Completion of Study PVO-1A-201; or new Adult Cohort subjects with confirmed R206H mutation who (1) have had at least two symptomatic flare-ups in the past 2 years, but no flare-up symptoms within the past 4 weeks; (2) have a Cumulative Analogue Joint Involvement for FOP (CAJIS) score of 6-16 (inclusive); and (3) are able to receive 5 mg palovarotene daily.
  • Adult Cohort subjects under the age of 18 years must have knee and hand/wrist radiographs confirming at least 90% skeletal maturity.
  • Abstinent or using two highly effective forms of birth control.
  • Accessible for treatment and follow-up. Subjects living at distant locations from the investigational site must be able and willing to travel to a site for the initial and all follow-up visits.
  • Written, signed, and dated informed consent and, for subjects who are minors, age-appropriate subject assent (performed according to local regulations).

Exclusion Criteria:

  • Weight <20 kg.
  • Intercurrent non-healed fracture.
  • Currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products for the duration of the study.
  • Exposure to synthetic oral retinoids in the past 30 days prior to Part B Screening (signature of the informed consent).
  • Concurrent treatment with tetracycline due to the potential increased risk of pseudotumor cerebri.
  • History of allergy or hypersensitivity to retinoids or lactose.
  • Concomitant medications that are inhibitors of CYP450 3A4 activity.
  • Amylase or lipase >2x above the upper limit of normal or with a history of pancreatitis.
  • Elevated aspartate aminotransferase or alanine aminotransferase >2.5x the upper limit of normal.
  • Fasting triglycerides >400 mg/dL with or without therapy.
  • Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.
Sexes Eligible for Study: All
6 Years to 65 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT02979769
PVO-1A-204
Yes
Not Provided
Not Provided
Clementia Pharmaceuticals Inc.
Clementia Pharmaceuticals Inc.
Not Provided
Not Provided
Clementia Pharmaceuticals Inc.
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP